e-ISSN: 2347-7857
p-ISSN: 2347-7849

Research & Reviews: Journal of Pharmaceutics and Nanotechnology

Modified or Altered Cancer Drugs can be used for the Treatment of Alzheimer's Disease

Rachana N*

Department of Biotechnology, Presidency College, Bangalore, India

Review Article

Received: 02/08/2016
Accepted: 05/08/2016
Published: 12/08/2016

***For Correspondence**

Rachana N, Department of Biotechnology, Presidency College, Bangalore, India

E-mail:
rachana.nandigama162@gmail.com, rachananandigama@yahoo.com

Keywords: Alzheimer's disease amyloid β-peptide disease-modifying drugs drug repositioning

ABSTRACT

Alzheimer's disease (AD) is an irreversible, progressive brain disorder that gradually devastates memory and thinking skills, and in the end the capacity to do the simplest tasks. It is most widely recognized type of neurodegenerative dementia, influencing around 30 million individuals around the world. In its initial stages, memory misfortune is gentle, however with late-stage Alzheimer's, people lose the capacity to bear on a discussion and react to their surroundings. Alzheimer's is the sixth driving reason for death in the United States. In spite of late advances in comprehension its atomic pathology, there are no mechanism based medications as of now that are accessible to stop the movement of AD. Since amyloid-β-peptide (Aβ), an essential part of feeble plaques, is thought to be a focal pathogenic culprit, a few sickness adjusting treatments are being created, including inhibitors of Aβ-delivering proteases and immunotherapies with hostile to Aβ antibodies. Drug repositioning or repurposing is viewed as an integral and sensible way to deal with and recognize new drug candidates for AD. This critique will talk about the clinical significance of an appealing hopeful compound and points of view in regards to the conceivable repositioning of oncology medications for the treatment of AD.

INTRODUCTION

Alzheimer's disease (AD) is a noteworthy kind of dementia that distresses around 30 million individuals overall [1-3]. Pathologically, this disease is portrayed by the presence of feeble plaques, made essentially out of amyloid β-peptide (Aβ), and neurofibrillary tangles, made for the most part out of phosphorylated tau protein, and in addition loss of neurotransmitters and neurons [4-6]. The few medications as of now endorsed for clinical use, for example, donepezil, give just symptomatic and transient advantages [7,8]. Since the collection of Aβ, especially the oligomeric species, seems to assume an essential pathogenic part in AD [9-11], it is an essential focus for infection changing therapeutics of AD. Aβ is created by serial cleavages of its antecedent, amyloid forerunner protein (APP), by β-secretase (or BACE1) and γ-secretase [12-15]. Along these lines, inhibitors or modulators of these proteases are being created. Other conceivable mediations incorporate Aβ immunotherapy to advance Aβ clearance and restraint of Aβ oligomerization [16-20]. No such medications have yet been demonstrated clinically powerful, notwithstanding the urgent need to discover new medicines for AD. It, therefore, appears an appealing technique to evaluate the counter Aβ impacts of medications affirmed for the treatment of different diseases. Such a "drug repositioning" or "repurposing" methodology is thought to have a few favourable circumstances, including lessened time and costs fundamental for clinical trials [21-24]. A paper by Hayes et al. portrays an intriguing oncology tranquilize that may possibly be utilized as an ailment changing medication in patients with AD [25-29].

A new candidate drug for the treatment of AD

There have been a few perceptions from various studies that propose a backwards relationship amongst disease and AD; tumor patients have been appeared to have a lower danger of growing AD, and comparably [30-34], those determined to have AD appear to have a lower danger of creating growth. Along these lines, it appeared to be conceivable that anticancer medications may apply good impacts on AD. By screening roughly 90 FDA-endorsed

oncology sedates, a gathering drove by Madepalli Lakshmana observed that BCNU (1,3 bis(2-chloroethyl)- 1-nitrosourea or carmustine), [35-39] an alkylating specialist at present used to treat patients with mind tumors, for example, threatening gliomas, has powerful movement in diminishing Aβ generation by refined cells overexpressing APP [40-43]. Ensuing examination of the instruments by which BCNU diminishes Aβ generation found that BCNU builds the discharge of APPα, a protein resulting from alternative α-cleavage of APP inside the Aβ locale, diminishes the levels of C-terminal sections of APP and expansions the outflow of juvenile APP on the cell surface. BCNU did not specifically influence the enzymatic exercises of β-, γ-and α-secretases [44-47]. As needs be, BCNU seems to lessen Aβ by changing the trafficking and processing of APP without straightforwardly influencing secretase activities. Likewise, BCNU was found to increase transforming growth factor (TGF) - β1 levels in cell media and cell separates an intriguing observation in view of the involvement of the TGF-β1 pathway in AD [48-52].

Taking after these cell-based investigations, the creators performed in vivo tests to figure out if BCNU could decrease Aβ generation in a transgenic mouse model, in which Aβ plaques show up as ahead of schedule as six months of age [53-58]. Intraperitoneal infusion of 0.5 mg/kg BCNU, a non-harmful measurements, for 60 days, from four to six months of age, brought about the checked lessening of Aβ plaque load in the mind. Besides, BCNU treatment diminished levels of Aβ and APP C-terminal parts and expanded levels of discharged APPα in mouse brains [59-63], reiterating the progressions saw in cell societies. Besides, BCNU treatment lessened the quantity of Iba1-positive microglia, showing that this operator smothers microglial initiation in the mouse mind. This impact might be identified with the TGF-β1 pathway [64-69], since TGF-β1 assumes a constitutive part in the concealment of aggravation. An unobtrusive increment in astroglial TGF-β1 creation in APP transgenic mice has been appeared to bring about a critical decrease of Aβ. In addition, a particular disability of the TGF-β1 flagging pathway has been shown in the AD cerebrum, and TGF-β1 has been found to apply neuroprotective impacts against different put-down, including Aβ harmfulness [70-74]. Along these lines, BCNU treatment may lessen Aβ creation through consolidated impacts on APP trafficking and preparing and on the TGF-β1 pathway.

Oncology drugs have potential utility for AD

The study by Hayes et al. distinguished BCNU as a potential anti- Aβ drug. In any case, a few inquiries should be explored, incorporating whether ceaseless treatment with BCNU can avoid subjective impedance in the mouse model and whether BCNU up-controls TGF-β1 in vivo [75-77]. Since BCNU is metabolized quickly in the cerebrum, the creators recommended that it's hostile to amyloidogenic impacts may come about because of the activity of one of its metabolites; in any case, such a compound stays to be distinguished. Security is a noteworthy issue to be considered. For the treatment of cerebrum tumors, patients are embedded with BCNU wafers to maintain a strategic distance from systemic reactions [78-81]. In spite of the fact that BCNU displayed a hearty Aβ-diminishing impact in vivo at non-lethal fixations, the wellbeing of long haul use has not yet been built up. On the off chance that a metabolite of BCNU with an intense hostile to Aβ activity is distinguished, a more secure compound with less danger might be created [82-86].

Potential AD treatment with existing oncology drugs gives off an impression of being a promising methodology. For example, treatment with bexarotene, an agonist of retinoid X receptors (RXRs) that is utilized to treat patients with T cell lymphoma [87-91], was as of late found to prompt obsessive and behavioural upgrades in transgenic mouse models of AD. Bexarotene stimulates the expression of apolipoprotein E (ApoE) and its lipid transporters ABCA1 and ABCG1, and facilitates Aβ clearance in an ApoE subordinate way [92-95]. This specialist likewise seems to advance microglial phagocytosis. Therefore, RXR agonists might be of helpful utility in the treatment of AD. Likewise, tranquilizes that activate retinoic corrosive receptors (RARs), for example, acitretin and tamibarotene, which are utilized to treat psoriasis and intense promyelocytic leukemia, respectively, have been reported to have beneficial effects on APP processing by enhancing non-amyloidogenic α-secretase processing of APP [96-98], presumably through the incitement of α-secretase (or ADAM10) expression. Since the organization of RAR agonists to APP transgenic mice diminishes Aβ levels in the cerebrum, they are promising competitor drugs for the treatment of AD. Phase II clinical trials are in progress to approve their clinical adequacy. Other oncology drugs with potential utility for AD incorporate imatinib and paclitaxel, yet both have the drawbacks of poor central nervous system penetration.

CONCLUSION

BCNU is an exceptional new expansion to the rundown of competitor oncology drugs with potential clinical viability in AD. More preclinical work, including elucidation of its systems of activity, is vital before BCNU continues to clinical trials [99, 100]. Obviously, different classes of medications other than those utilized for chemotherapy are viewed as potential applicant drugs for AD. Future thorough endeavors to create sickness altering drugs through medication repositioning or repurposing may prompt the rise of effective treatments for AD.

REFERENCES

1. Brookmeyer R, et al. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2011;7:61.
2. LaFerla FM, et al. Alzheimer's disease: abeta, tau and synaptic dysfunction. Trends Mol Med. 2005;11:170.
3. Cacabelos R. The Complexity of Alzheimer's Disease Pharmacogenomics and Metabolomics in Drug Development. Metabolomics. 2016;6:e145.
4. Hardy J, et al. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353.
5. Melamed I. Alzheimer's Disease of the Immune System: A New Variant of Immune Deficiency. Immunother Open Acc . 2016;2:115.
6. Walsh DM, et al. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172.
7. Archer T. Amelioration of Symptoms and Biomarkers of Alzheimers Disease by Physical Exercise. Open access. 2016;2:e105.
8. De Strooper B, et al. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99.
9. Salomone S, et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2012;73:504
10. Corbett A. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov. 2012;11:833.
11. Appleby BS. A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35:1.
12. Roe CM, et al. Alzheimer disease and cancer. Neurology. 2005;64:895.
13. Driver JA, et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442.
14. Caraci F, et al. TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease. CNS Neurosci Ther. 2011;17:237.
15. Rubio-Perez JM, et al. A review: inflammatory process in Alzheimer's disease, role of cytokines. Scientific World Journal. 2012;2012:756357.
16. Wyss-Coray T, et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:614.
17. Cramer PE, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503.
18. Miller MD, et al. Preparing for the Rise in Alzheimers Disease Cases: A Proposal for Training Support Personnel. J Gerontol Geriatr Res. 2015;4:195.
19. Tian M, et al. Alzheimer's Disease and Dementia, Under-Recognized Public Health Crisis in China. J Gerontol Geriat Res. 2014;3:162.
20. Kim H, et al. Differences in C-reactive Protein Level in Patients with Alzheimer's Disease and Mild Cognitive Impairment. J Psychiatry. 2015;18:194.
21. Tippmann F, et al. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 2009;23:1643.
22. Kawahara K, et al. Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain beta-amyloid peptides in APP23 mice. Biol Pharm Bull. 2009;32:1307.
23. Block A, et al. Abnormal Protein Profiles in Hippocampus of Mouse Models of Down Syndrome: Similarities with Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2014;4:138.
24. Li X, et al. Amyloidopathy in the Eye of Alzheimer's Disease. J Addict Res Ther. 2012;S5:005.
25. Perea RD, et al. A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2013;3:123.
26. Manaye KF, et al. Possible APOE Genotype and Sex Dependent Effects of 17-α- estradiol on Alzheimers Disease Pathology. J Alzheimers Dis Parkinsonism. 2013;3:e130.
27. Jester H, et al. Does The Mediterranean Diet or Botanicals Influence Alzheimer's Disease? Clin Pharmacol Biopharm. 2016;5:e123.
28. Wu Y, et al. Observation Study of the Retina with the Alzheimer's Disease or Amnestic Mild Cognitive Impairment Patients. J Clin Exp Ophthalmol. 2016;7:545.
29. Tarumi T, et al. Alzheimer's Disease and Habitual Exercise: Relationship Mediated and Fostered by Vascular Risk Profiles? J Gerontol Geriatric Res. 2012;1:e111.

30. Singh I. Challenges to Establish Definite Diagnosis of Alzheimer's Disease. J Gerontol Geriatric Res. 2012;1:e105.
31. Dessouky MM, et al. Feature Extraction of the Alzheimer's Disease Images Using Different Optimization Algorithms. J Alzheimers Dis Parkinsonism. 2016;6:230.
32. Barbosa CD. Challenges with Big Data in Oncology. J Orthop Oncol. 2016;2:112.
33. Dixon ZL, et al. Patients more Likely to Prefer Surgery to Novel Photodynamic Therapy. J Clin Exp Dermatol Res. 2016;7:358.
34. Fedele M, et al. The Tumor Suppressive Role of PATZ1 in Thyroid Cancer: A Matter of Epithelial-Mesenchymal Transition. Chemo Open Access. 2016;5:198.
35. Semmar A, et al. Laryngeal Chondrosarcoma: A Case Report. J Clin Case Rep. 2016;6:757.
36. Maździarz A, et al. BenignMetastasizing Leiomyomas of the Lungs: A Case Report. J Cancer Sci Ther. 2016;8:080
37. De Cunto Taets GG. The Nursing Care in Front of the Dying Process in Oncology. J Nurs Care. 2016;5:337.
38. Lin J. Biomarker-Based Clinical Trial Designs in Oncology. J Biom Biostat. 2016;7:296.
39. Alessandro P, et al. Hemopericardium after Lung Lobectomy. J Pulm Respir Med. 2016;6:331.
40. Nebigil CG, et al. Quo Vadis, Cardio-Oncology?. Adv Oncol Res Treat. 2016;1:102.
41. Pettersson M, et al. Physicians' Experiences of Do-Not-Resuscitate (DNR) Orders in Hematology and Oncology Care – A Qualitative Study. J Palliat Care Med. 2016;6:275.
42. Altwerger G, et al. Surgical Site Infections in Gynecologic Oncology: Editorial. Gynecol Obstet (Sunnyvale). 2016;6:e117.
43. Mandat T, et al. Pallidal or Subthalamic Deep Brain Stimulation for the Generalized Dystonia Treatment. J Neurol Neurophysiol. 2016;7:382.
44. Caff G, et al. Isolated Comminuted Tarsal Navicular Fracture: A Case Report. J Clin Case Rep. 2016;6:745.
45. Jensen SS, et al. Targeting Monocytes with TLR7 Ligands as a Novel Opportunity in Immuno-Oncology. Immunother Open Acc . 2016;2:114.
46. Silva AL, et al. RAC1b: A New Player in the Scenario of Thyroid Tumorigenesis?. Adv Mol Diag. 2016;1:103.
47. Guo RJ. Diagnostic Pathology–Molecular Oncology. J Cytol Histol. 2016;S5:012.
48. Nennhaus M, et al. End-of-Life Decision Making in Pediatric Oncology and Intensive Care in Germany – Results of a Multi-professional Questionnaire Study. J Palliat Care Med. 2016; 6:251.
49. Dash SK, et al. Idiopathic Pulmonary Hypertension Induced Thrombocytopenia - A Case Report. J Pulm Respir Med. 2016;6:322.
50. Mukherjee G, et al. Analysis of Clinico-Pathological Characteristics of Indian Breast Cancers Shows Conservation of Specific Features in the Hormone Receptor Sub-Types. J Integr Oncol. 2016;5:159.
51. Lai-Tiong F. Chemotherapy-Induced Nausea and Vomiting: An Oncology-Day Unit Experience. J Integr Oncol. 2016;5:158.
52. Salutari V, et al. Commentary on Bevacizumab in Ovarian Cancer: Focus on Clinical Data and Future Perspectives. Trends Gynecol Oncol. 2016;1:103.
53. Smichkoska S, et al. Long Term Trastuzumab in Metastatic Setting of the Patients with HER2 Positive Breast Cancer. J Blood Lymph. 2016;1:103.
54. Wold ED, et al. Antibody Therapeutics in Oncology. Immunother Open Acc. 2016;2:108.
55. Fabio M, et al. Fertility Sparing Options in Gynecologic Oncology. Trends Gynecol Oncol. 2016;1:e101.
56. Marcus JD. Psychosocial Oncology and Palliative Communication. J Palliat Care Med. 2016;6:246.
57. Panchal HP. Trailing the Path to Preventive Oncology. Adv Cancer Prev. 2016;1:104.
58. Cifuentes D, et al. Targeting Hypertension to Manage Alzheimer's Disease: Rational and Promise. J Alzheimers Dis Parkinsonism. 2016;6:228.
59. Valencic M. Excessive Blood Preassure Lowering: Possible Cause of Alzheimer's Disease. J Gerontol Geriatr Res. 2016;5:265.
60. Narayan M, et al. Identification of Novel Cdc37 Interacting Proteins and Pathways in Human Alzheimer's Disease Brain Tissue Using Mass Spectrometry. J Data Mining Genomics & Proteomics. 2016;7:193.
61. Passafiume D, et al. Recognition of Environmental Emotional Sounds in Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2016;6:217.
62. Hussain G, et al. Synthesis and Molecular Docking Study of Some New 4-{[4-(2-Furoyl)-1-piperazinyl]methyl}-N-(substituted-phenyl)benzamides as Possible Therapeutic Entrants for Alzheimer's Disease. Med chem (Los Angeles). 2016;6:129.
63. Shinno H, et al. Alterations in Rapid Eye Movement Sleep Parameters Predict for Subsequent Progression from Mild Cognitive Impairment to Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2016;6:218.

64. Suzuki N, et al. Cellular Transplantation as the Treatment of Alzheimer's Disease in Mouse Models. J Alzheimers Dis Parkinsonism. 2016;6:219.
65. Lan YL, et al. The Great Significance of Research into the Physiological Relevance between AQP4 and Vasopressin for Studying Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2015;5:192.
66. Roses AD. APOE and TOMM40 in Alzheimer's Disease: A Case of Mistaken Identity, Using Precision Tools but with Loss of Accuracy. J Pharmacogenomics Pharmacoproteomics. 2015; 6:e148.
67. Zerovnik E, et al. Recent Developments in Treating Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2016;6:220.
68. Woods JJ, et al. Cigarette Smoking: A Causal Factor for Alzheimers Disease? . JGerontol Geriatr Res. 2016;5:286.
69. Suzuki H, et al. A Comparison of Lamotrigine or Sodium Valproate on the Efficacy in Alzheimer's disease with Behavioral and Psychological Symptoms of Dementia: A Retrospective Open-Label Study Running Title: Efficacy of Anticonvulsants for BPSD. J Gerontol Geriatr Res. 2015;4:253.
70. Bambo MP, et al. Retinal and Optic Disc Alterations in Alzheimer's Disease: the Eye as a Potential Central Nervous System Window. J Alzheimers Dis Parkinsonism. 2016;6:223.
71. Kljajevic V. An Emerging Model of Word Retrieval in Preclinical Alzheimer's Disease. J Alzheimers Dis Parkinsonism. 2016;6:225.
72. Lo CY, Campen C, et al. Female Gender and Hispanic Ethnicity are Associated with Increased Risk of Subacute Methotrexate Encephalopathy. Toxicol open access. 2015; 1: 104.
73. Soldà C, et al. Good and Prolonged Response to Low Dose Capecitabine as Second Line Therapy in a Patient with Advanced Hepatocellular Carcinoma. Chemo Open Access. 2015; 5:181.
74. Klafki HW, et al. Therapeutic approaches to Alzheimer's disease. Brain. 2006;129.
75. De Domenico EBL, et al. Professional Competence in Oncology: Challenges for Education . Chemo Open Access. 2015;5:179.
76. Abyad A. Alzheimer's the Road Ahead in the Middle East. J Alzheimers Dis Parkinsonism. 2016;6:241.
77. Allen HB, et al. Alzheimer's Disease: A Novel Hypothesis Integrating Spirochetes, Biofilm, and the Immune System. J Neuroinfect Dis. 2016;7:200.
78. Dow CT. CMV Driven Immunosenescence and Alzheimer's Disease. J Neuroinfect Dis. 2015; 6:195.
79. Kizilbash N, et al. Molecular Docking to Test for Efficacy of Porphyrin Compounds to Cure Alzheimer's Disease. J Biotechnol Biomater. 2015;5:199.
80. Sourdet S, et al. Effectiveness of a Specific Care Plan in Alzheimer's Disease in the Oldest Old. J Alzheimers Dis Parkinsonism. 2015;5:194.
81. Benussi A, et al. Transcranial Magnetic Stimulation in Alzheimer's Disease and Cortical Dementias. J Alzheimers Dis Parkinsonism. 2015;5:197.
82. Cintra MTG, et al. P300 Evoked Potential and Risk of Mild Cognitive Impairment Progression to Alzheimer's Dementia: A Literature Review. J Neurol Neurophysiol. 2015;6:322.
83. Begum MM, et al. Anticholinesterase and Antioxidant Potentials of a Medicinal Plant Abroma augusta: Implications for the Alternative Treatment Therapy of Cognitive Deficits in Alzheimer's disease. Clin Pharmacol Biopharm. 2015;4:148.
84. Zhang Q, et al. Alzheimer's Model Develops Early ADHD Syndrome. J Neurol Neurophysiol. 2015;6:329.
85. Naijing Li, et al. Brain Metabolomics Study on the Protective Effects of Ginsenosides Rg1 and Rb1 in an Alzheimer's Disease Mouse Model. Pharm Anal Chem Open Access. 2015;1:108.
86. Zhou LL. GluN2B-NMDA Receptors in Alzheimer's Disease: What Do they Got to Do with AD?. J Neurol Disord. 2015;3:e118.
87. Juma KK. A Current Understanding of Alzheimer's Disease and the Prospects of Phytopharmacological Intervention as a Management Strategy. J Neurol Disord. 2015;3:244.
88. Ryan JJ, et al. Temporal Disorientation Base Rates in Alzheimer's Disease and Parkinson's Disease J Gerontol Geriat Res. 2015;4:221.
89. Lukiw WJ. Towards Effective Treatment Strategies for Alzheimer's disease (AD). J Develop Drugs. 2012;1:e102.
90. Norollahi SE, et al. The Role of MicroRNAs in Cancer Progression. J Clin Exp Oncol. 2016;5:2.
91. Kumar R, et al. Quantum Magnetic Resonance Therapy: Targeting Biophysical Cancer Vulnerabilities to Effectively Treat and Palliate. J Clin Exp Oncol. 2016;5:2.
92. Brown MA. Diversifying Graduate Education: The Future of Experimental Oncology. J Clin Exp Oncol. 2013;2:3.
93. Schmidt C, et al. Relating the Pendulum of Democracy with Oncology Research. J Clin Exp Oncol. 2015;4:3.

94. Schmidt C, et al. The Sins of Omission. J Clin Exp Oncol. 2015;4:1.
95. Cohen KL, et al. Monitoring Reader Metrics in Blinded Independent Central Review of Oncology Studies. J Clin Trials. 2015;5:230.
96. Tutar Y. Diazepine Derivative Compounds as Heat Shock Protein 90 Inhibitor in Oncology. Drug Des. 2015;4:e127.
97. Nawab DH. The Pharmaceutical Applications of Next Generation Sequencing in Oncology Drug Designing and Development. Next Generat Sequenc & Applic. 2015;2:116.
98. Fioranelli M, et al. Theoretical-Scientific Foundations about the Use of Low-Dose in Oncology. Microinflammation. 2014;1:e101.
99. Feng X, et al. Future Medicine for Today's Cancer Patients: Therapeutic Application of Pharmacogenomics in Oncology. J Pharma Care Health Sys. 2014;1:119.
100. Carasevici E. Natural Autoantibodies are Biomarkers of Immunosurveillance System. Biochem Pharmacol (Los Angel). 2013;2:e147.